Institut für Atemwegsforschung GmbH Report issue

Academic/Hospital Phase 2 Phase 4

Organization Overview

First Clinical Trial
2006
NCT00355771
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

Institut fuer Atemwegsforschung GmbH

Active Ingredients

Drugs in Phase 4 Trials (1)

levocetirizine (xyzal) (2 trials)

Drugs in Phase 2 Trials (1)

chf5259 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Lung Diseases, Obstructive (Phase 2)

Nasal Obstruction (Phase 4)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Rhinitis (Phase 4)

Rhinitis, Allergic (Phase 4)

Rhinitis, Allergic, Perennial (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 3
  • # of Trial APIs: 2